antihypertensive strategy

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)